🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the fight against superbug strains of the bacteria, according to scientists.

An International Health Concern

Cases of gonorrhoea are increasing globally, with figures suggesting over 82 million new cases each year. Notably increased rates are observed in Africa and countries within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an critical and opportune development in the face of rising global incidence, escalating drug resistance and the extremely scarce available drugs currently available.”

Health officials are particularly alarmed about the increase in drug-resistant strains. The World Health Organization has classified it as a "critical concern". A tracking program found that resistance to standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Treatment Options Secure Approval

Zoliflodacin, marketed under the name a brand name, was approved by the American regulatory agency in December for use against gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Scientists anticipate that specific application of this new drug will help delay the spread of drug resistance.

Another new antibiotic, developed by the pharmaceutical company GSK, also received approval in close succession. This medication, which is employed against UTIs, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment was the result of a new, not-for-profit approach for medication research. The charitable organization GARDP collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This approval signifies a significant shift in the therapy of multidrug-resistant gonorrhoea, which until now has been evolving faster than antibiotic development.”

Clinical Trial Results and Worldwide Availability

As per data released by a prominent scientific publication, the new drug cured more than 90% of cases of the STI. This places it at an equal footing with the current standard treatment, which combines an injection and a pill. The trial enrolled nearly 1,000 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, GARDP has the authority to make available and distribute the drug in a wide range of low-income and middle-income countries.

Doctors directly involved have voiced hope. Access to a easy-to-administer therapy of this kind is hailed as a "game-changer" for public health efforts. This is considered essential to alleviate the strain of the disease for people and to stop the proliferation of untreatable gonorrhoea globally.